Abstract
The introduction of biologic therapy has revolutionized the treatment of many chronic diseases, including several dermatological disorders. Biological agents promise to satisfy medical needs previously unmet by conventional medicines. Unfortunately, these agents are expensive and out of reach for the majority of patients who need them. Biosimilars are copies of the innovator biological agents and represent an important advance in the field of biological therapeutics. Although they are similar to the original biologic, differences in terms of structure, efficacy, safety and immunogenicity remain a concern. Thus, biosimilars cannot be regarded as bio-generics. Awareness of the key differences between a biosimilar and its reference biological agent is essential for optimal treatment and safety of patients. The increasing availability of biosimilars provides patients and doctors with less expensive alternatives and increases the accessibility of biologic therapy to needy patients. In this review, we discuss the concept of biosimilars, the need for appropriate regulatory pathways and their current status in dermatology.
References
Sep 9, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Michele KesslerHuub Schellekens
Jul 12, 2007·Kidney & Blood Pressure Research·Michał Nowicki
Sep 18, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H MellstedtH Ludwig
Jul 28, 2009·Current Drug Abuse Reviews·Michael Givel
Jul 30, 2010·The Journal of Dermatological Treatment·Nitin RanjanMonika Misra
Sep 11, 2010·Nature Biotechnology·Killugudi Jayaraman
Jan 17, 2012·Journal of the American Academy of Dermatology·Bruce E StroberCraig Leonardi
Oct 5, 2012·PDA Journal of Pharmaceutical Science and Technology·Anurag Rathore
Apr 5, 2013·The Journal of Dermatological Treatment·Kyriaki TzoganiFrancesco Pignatti
Apr 23, 2013·Expert Opinion on Biological Therapy·Edward M VitalPaul Emery
May 10, 2013·Drug and Therapeutics Bulletin
Mar 25, 2014·Autoimmunity Reviews·Gionata FiorinoUNKNOWN SIR, SIDeMaST, and IG-IBD
Mar 21, 2015·Cancer Discovery·Janet Colwell